lncRNA PCAT14 Is a Diagnostic Marker for Prostate Cancer and Is Associated with Immune Cell Infiltration.

OBJECTIVE

To investigate the relationship between the long noncoding RNA (lncRNA) () and the clinical characteristics of prostate cancer and immune cell infiltration.

METHODS

The relationship between expression and the clinicopathological characteristics of prostate cancer was analyzed based on The Cancer Genome Atlas (TCGA) database. Receiver operating characteristic (ROC) curves were used to evaluate the value of as a diagnostic marker for prostate cancer. The relationship between and immune cell infiltration was analyzed to explore the effect of on the immune-related functions of prostate cancer.

RESULTS

The ROC curve showed that had a significant diagnostic ability (area under curve = 0.818) for prostate cancer. A reduced expression of in prostate cancer was related to T stage, N stage, primary therapy outcome, residual tumor, Gleason score, and age. The expression of was independently associated with the progression-free interval in prostate cancer patients. The infiltration of immune cells in prostate cancer showed a significant negative correlation between the expression of and plasmacytoid dendritic cells, activated dendritic cells, regulatory T cells, and neutrophils.

CONCLUSIONS

is highly expressed in prostate cancer and is expected to be a diagnostic marker. might promote the development of prostate cancer through chemokines, antimicrobials, and cytokines that affect the infiltration of immune cells.